DCVC

DCVC (Data Collective Venture Capital) is a deep tech venture capital firm based in Palo Alto, California, founded in 2010 by Matthew Ocko and Michael Driscoll. The firm focuses on investing in groundbreaking technologies that address significant global challenges across various sectors, including artificial intelligence, space, climate, engineering, and more. DCVC manages multiple funds, including DCVC V, which is a $725 million fund aimed at disrupting substantial sectors of the global economy. The firm emphasizes backing startups that employ computational and engineering approaches to solve high-stakes problems. Notable portfolio companies include Pivot Bio, Planet, Zymergen, Atomwise, Rocket Lab, and Recursion Pharmaceuticals, all of which are leaders in their respective industries. DCVC also has a specialized branch, DCVC Bio, co-founded with Dr. John Hamer and Dr. Kiersten Stead, focusing on AI-enabled life sciences platforms. This branch aims to bring new medicines to market and commercialize biological breakthroughs, with companies like AbCellera, Chroma Medicine, and Totus Medicines leading the charge​. The firm’s investment strategy is driven by a belief that venture capital can address urgent global problems profitably and equitably, turning challenges into opportunities while delivering strong returns. DCVC continues to expand its team with experts across various fields to support its growing portfolio and mission​.